Phase 2a trial of Jotrol for Parkinson’s begins enrolling patients in the U.S.

Jun 4, 2026

Experimental treatment's safety, tolerability will be assessed

Written by Andrea Lobo | June 2, 2026

  • A Phase 2a trial of Jotrol is enrolling Parkinson's disease patients.
  • Jotrol aims to reduce brain inflammation and oxidative stress.
  • The trial will assess Jotrol's safety, tolerability, and effects on motor/non-motor symptoms.

Patient enrollment has started in a Phase 2a clinical trial evaluating Jotrol, an oral formulation of resveratrol developed by Jupiter Neurosciences as a treatment for Parkinson’s disease, the company has announced.

The RESET trial (NCT07592767) is recruiting up to 30 patients at three sites in the U.S.: Georgetown University MedStar Hospital in Washington, DC; Montgomery and Franklin Square MedStar Hospitals in Maryland; and MedStar McLean Clinic in Virginia.

The trial, which will assess the treatment’s safety, tolerability, and pharmacological properties, is expected to be completed in the first half of 2027.

“With enrollment now underway in the Phase 2a RESET trial we have reached a critical operational milestone. We look forward to generating the clinical data needed to evaluate JOTROL’s potential and to serve patients, providers, and the broader scientific community,” Christer Rosén, Jupiter’s CEO, said in a company press release.

Jotrol preserved motor function in mouse model

Parkinson’s is marked by the loss of brain cells called dopaminergic neurons, which produce dopamine, a signaling molecule involved in motor control. Lack of dopamine signaling leads to the disease’s symptoms, including movement problems and cognitive issues.

While the exact causes of Parkinson’s aren’t fully known, research suggests that excessive brain inflammation and oxidative stress, a type of cellular damage, help drive nerve cell damage and contribute to disease progression.

Resveratrol is a compound found in certain plants, including grapes, with anti-inflammatory and antioxidant properties, meaning it can reduce inflammation and oxidative stress. However, its use has been limited due to digestive issues when taken orally at high doses.

Continue Reading Here